Abstract

No universal strategy exists for humanizing mouse antibodies, and most approaches are based on primary sequence alignment and grafting. Although this strategy theoretically decreases the immunogenicity of mouse antibodies, it neither addresses conformational changes nor steric clashes that arise due to grafting of human germline frameworks to accommodate mouse CDR regions. To address these issues, we created and tested a structure-based biologic design approach using a de novo homology model to aid in the humanization of 17 unique mouse antibodies. Our approach included building a structure-based de novo homology model from the primary mouse antibody sequence, mutation of the mouse framework residues to the closest human germline sequence and energy minimization by simulated annealing on the humanized homology model. Certain residues displayed force field errors and revealed steric clashes upon closer examination. Therefore, further mutations were introduced to rationally correct these errors. In conclusion, use of de novo antibody homology modeling together with simulated annealing improved the ability to predict conformational and steric clashes that may arise due to conversion of a mouse antibody into the humanized form and would prevent its neutralization when administered in vivo. This design provides a robust path towards the development of a universal strategy for humanization of mouse antibodies using computationally derived antibody homologous structures.

Highlights

  • Antibodies render higher specificity than small molecules against a given biological target

  • A total of 17 mouse antibody homology models generated via the Prediction of Immunoglobulin Structures (PIGS) and Rosetta Antibody Modeling (RAM) servers were carefully examined for modeling errors

  • The 3I75 model obtained via the PIGS server, as well as the 4DCQ and 3MNV models via the RAM server, contained a broken chain or modeling failure

Read more

Summary

Introduction

Antibodies render higher specificity than small molecules (drugs) against a given biological target. The mouse is the most favored model system for producing specific antibodies to an antigen of interest. Administration of mouse mAbs in patients can lead to allergic reactions against the therapeutic antibody, otherwise known as the human anti-mouse antibody (HAMA) response [1]. To address this problem, chimeric antibodies have been designed, which could lessen the HAMA response but not eliminate it [2]. As the CDR paratope usually binds and engages the antigen epitope, the mouse CDRs in the humanized antibody are minimally exposed to the human immune system and, in theory, should be non-allergenic in nature

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call